Lankacidinol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598206

CAS#: 23498-37-5

Description: Lankacidinol is an antibiotic with antitumor and immunosuppressive activities.


Chemical Structure

img
Lankacidinol
CAS# 23498-37-5

Theoretical Analysis

MedKoo Cat#: 598206
Name: Lankacidinol
CAS#: 23498-37-5
Chemical Formula: C25H35NO7
Exact Mass: 461.2414
Molecular Weight: 461.55
Elemental Analysis: C, 65.06; H, 7.64; N, 3.03; O, 24.26

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Lankacidinol; T-2636 F; T 2636 F; T2636 F; Antibiotic T 2636F;

IUPAC/Chemical Name: (R)-N-((1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl)-2-hydroxypropanamide

InChi Key: FUDDPCATVZFGCZ-SQFDTGPGSA-N

InChi Code: InChI=1S/C25H35NO7/c1-14-6-9-18(28)10-8-15(2)12-21(26-23(31)17(4)27)25(5)22(30)16(3)20(33-24(25)32)13-19(29)11-7-14/h6-8,10-12,16-21,27-29H,9,13H2,1-5H3,(H,26,31)/b10-8+,11-7+,14-6+,15-12+/t16-,17-,18+,19-,20-,21-,25+/m1/s1

SMILES Code: O[C@H](C)C(N[C@H](/C=C(C)/C=C/[C@@H](O)C/C=C(C)/C=C/[C@@H](O)C[C@@]1([H])O2)[C@](C([C@@H]1C)=O)(C)C2=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 461.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Oostu K, Matsumoto T, Harada S, Kishi T. Antitumor and immunosuppressive activities of lankacidin-group antibiotics: structure-activity relationships. Cancer Chemother Rep. 1975 Sep-Oct;59(5):919-28. PubMed PMID: 1148.

2: Hayashi T, Okada J, Kondo S, Yamazaki T. Role of intestinal excretion in the effect of subcutaneously administered sedecamycin on cecal infection caused by Treponema hyodysenteriae in mice. Antimicrob Agents Chemother. 1991 Aug;35(8):1601-4. PubMed PMID: 1929332; PubMed Central PMCID: PMC245226.

3: Okada J, Kondo S. Liquid chromatographic method for determining the macrolide antibiotic sedecamycin and its major metabolites in swine plasma and tissues. J Assoc Off Anal Chem. 1987 Sep-Oct;70(5):818-24. PubMed PMID: 3680117.

4: Tatsuno S, Arakawa K, Kinashi H. Analysis of modular-iterative mixed biosynthesis of lankacidin by heterologous expression and gene fusion. J Antibiot (Tokyo). 2007 Nov;60(11):700-8. PubMed PMID: 18057700.

5: McFarland JW, Pirie DK, Retsema JA, English AR. Side chain modifications in lankacidin group antibiotics. Antimicrob Agents Chemother. 1984 Feb;25(2):226-33. PubMed PMID: 6370129; PubMed Central PMCID: PMC185479.

6: Yamauchi Y, Nindita Y, Hara K, Umeshiro A, Yabuuchi Y, Suzuki T, Kinashi H, Arakawa K. Quinoprotein dehydrogenase functions at the final oxidation step of lankacidin biosynthesis in Streptomyces rochei 7434AN4. J Biosci Bioeng. 2018 Jun 2. pii: S1389-1723(18)30057-4. doi: 10.1016/j.jbiosc.2018.03.006. [Epub ahead of print] PubMed PMID: 29871824.

7: Zheng K, Shen D, Hong R. Biomimetic Synthesis of Lankacidin Antibiotics. J Am Chem Soc. 2017 Sep 20;139(37):12939-12942. doi: 10.1021/jacs.7b08500. Epub 2017 Sep 6. PubMed PMID: 28853876.

8: Lu C, Li JM, Qi H, Zhang H, Zhang J, Xiang WS, Wang JD, Wang XJ. Two new lankacidin-related metabolites from Streptomyces sp. HS-NF-1178. J Antibiot (Tokyo). 2018 Mar;71(3):397-401. doi: 10.1038/s41429-017-0004-0. Epub 2018 Jan 18. PubMed PMID: 29348529.